Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Oct 09, 2026
TickeronGET DAILY SIGNALS
Moderna (MRNA) Climbs +45% in 30 Days on Melanoma Data and Nasdaq-100 Entry

Moderna (MRNA) Climbs +45% in 30 Days on Melanoma Data and Nasdaq-100 Entry

Key Takeaways

  • Moderna shares climbed about 45% over the last 30 days, closing at $197.00 on October 8, 2026, up from $135.61 on September 9.
  • The advance extends a roughly 157% gain over the past quarter, driven largely by positive Phase 3 melanoma data announced August 19.
  • The core catalyst is the individualized mRNA cancer therapy intismeran autogene, developed with Merck (MRK), which succeeded in the Phase 3 INTerpath-001 trial in combination with Keytruda.
  • Supportive factors include a series of analyst price-target increases, planned Nasdaq-100 inclusion effective October 9, and a new chief operating officer focused on manufacturing scale-up.
  • Offsetting pressure came from a Citigroup downgrade to Sell on valuation, while the consensus analyst rating remains Hold with an average target below the current share price.

Moderna’s mRNA Platform and Shift Toward Oncology

Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company built around messenger RNA (mRNA) technology, which instructs cells to produce proteins that train the immune system or treat disease. Its commercial portfolio includes the Spikevax COVID-19 vaccine and mRESVIA, a respiratory syncytial virus (RSV) vaccine, alongside a respiratory franchise in transition following the normalization of pandemic-era demand.

Investor attention has shifted toward Moderna's oncology pipeline, led by intismeran autogene, an individualized neoantigen therapy developed in collaboration with Merck (MRK). The therapy is designed around mutations unique to each patient's tumor and is being studied across multiple cancer types. This broadening from vaccines into oncology underpins why the market has repriced the stock from a declining respiratory business into a potential platform story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

MRNA Stock Price Moves: 30-Day and Quarterly Trends

Over the last 30 days, Moderna shares rose approximately 45%, from a closing price of $135.61 on September 9 to $197.00 on October 8, 2026. The move was not a straight line: the stock climbed through late September, reached an intraday high around $212 on October 6, and then pulled back as investors locked in profits before recovering into the close of the period.

The quarterly trend is even more pronounced. Roughly three months earlier, on July 9, the stock closed near $76.56, meaning it has risen approximately 157% over the quarter. That advance is dominated by a single session: on August 19, shares surged 176.97% to close at $174.38 after the company and Merck announced positive Phase 3 melanoma data. Since that breakout, the stock has largely traded between roughly $130 and $210 as the market digests the oncology opportunity.

Drivers Behind the Recent 30-Day Advance

The 30-day advance reflects a continuation of the repricing that began in August, reinforced by several verified developments. Analysts moved their models higher in the wake of the melanoma readout, with RBC Capital raising its target from $45 to $130 and William Blair upgrading the stock to Outperform. More recently, Morgan Stanley adjusted its target to $95 from $89 on October 7.

Index-related demand added another layer. Nasdaq confirmed that Moderna would join the Nasdaq-100 effective October 9, replacing Warner Bros. Discovery (WBD). Because hundreds of funds track the index, the change prompted expectations of passive inflows. Moderna also appointed Juan Andres to a newly created chief operating officer role to oversee manufacturing ahead of a potential launch of intismeran autogene, while three abstracts on the therapy were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress.

The rally was not without friction. On September 30, Citigroup downgraded Moderna to Sell while raising its target from $60 to $80, arguing the stock had gotten ahead of the pipeline's near-term commercial prospects, and the shares saw profit-taking in early October. The broader consensus remains a Hold, with an average 12-month target around $121. From what I see, this valuation debate remains a key point to monitor.

The Quarter’s Defining Catalyst: Phase 3 Melanoma Success

The quarter's defining event occurred on August 19, when Moderna and Merck reported that the Phase 3 INTerpath-001 trial of intismeran autogene in combination with Keytruda met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival in more than 1,100 patients with resected high-risk melanoma. It marked the first Phase 3 success for an individualized neoantigen therapy and the first for any mRNA-based cancer treatment.

The news revalued the company almost overnight, lifting its market capitalization from roughly $25 billion toward $70 billion. Merck (MRK) shares rose about 12.6% that day, and mRNA peers such as BioNTech (BNTX) also advanced. The move signaled that investors were beginning to price Moderna not as a fading COVID vaccine maker but as an oncology platform with optionality across lung, kidney, and bladder cancer programs.

Factors Likely to Influence the Next Moves

Several factors are likely to shape Moderna's path ahead. Regulatory progress is central: the company and Merck have indicated they will engage regulators in the coming months, with full Phase 3 data expected at an upcoming medical meeting and overall survival results anticipated later in the decade. Manufacturing scale-up for an individualized therapy, a key operational challenge, is now under a dedicated COO.

Investors will also monitor the respiratory franchise during the fall immunization season and the company's next quarterly results, given that Moderna remains unprofitable and carries a negative forward earnings profile. Valuation itself is a live debate, with the average analyst target sitting well below the current price even after recent target increases. Competitive mRNA oncology programs, regulatory timelines, and broader biotech rate sensitivity round out the list of variables worth watching. None of this constitutes a prediction, but these are the verified drivers most likely to influence sentiment in the quarters ahead. I’m watching this closely as more data emerges.

Exploring Tickeron’s AI Trading Bots for Biotech Volatility

In my experience, platforms like Tickeron can help cut through the noise when tracking fast-moving names in biotech. I’ve found their AI Trading Bots particularly useful for comparing automated strategies across volatile sectors, including healthcare stocks like Moderna. The tools surface top-performing bots with different timeframes and approaches, which lets me review how algorithmic systems handle swings without relying on any single signal. It’s been a practical way to cross-check my own analysis on names showing sharp moves.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MRNA

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


MRNA's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for MRNA moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

MRNA moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

MRNA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +11.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 217 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 108 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.010) is normal, around the industry mean (3.596). P/E Ratio (-31.853) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of transformative medicines for patients

Industry Biotechnology

Industry
Biotechnology
Address
325 Binney Street
Phone
+1 617 714-6500
Employees
4700
Web
https://www.modernatx.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.